-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Maintains Buy on ProKidney, Lowers Price Target to $8

Benzinga·10/28/2026 21:39:33
Citigroup analyst Yigal Nochomovitz maintains ProKidney (NASDAQ:PROK) with a Buy and lowers the price target from $10 to $8.